Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - epoetin alfa 84 µg/ml - solution for injection - 84 mcg/ml - active: epoetin alfa 84 µg/ml excipient: dibasic sodium phosphate dihydrate glycine hydrochloric acid monobasic sodium phosphate dihydrate nitrogen polysorbate 80 sodium chloride sodium hydroxide water for injection - binocrit is indicated for: · the treatment of severe anaemia of renal origin accompanied by clinical symptoms in patients with renal insufficiency not yet undergoing dialysis · anaemia associated with chronic renal failure in paediatric and adult patients on dialysis · anaemia in patients with non-myeloid malignancies where anaemia is due to the effect of concomitantly administered chemotherapy · adult patients with mild-to-moderate anaemia (haemoglobin > 100 to < 130 g/l) scheduled for elective surgery with an expected moderate blood loss (2-4 units or 900 to 1800 ml) to reduce exposure to allogeneic blood transfusion and to facilitate erythropoietic recovery · to augment autologous blood collection and to limit the decline in haemoglobin in anaemic adult patients undergoing major surgery who are not expected to pre-deposit their complete peri-operative blood needs.

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - carboplatin 10 mg/ml;   - concentrate for injection - 10 mg/ml - active: carboplatin 10 mg/ml   excipient: water for injection - - treatment of advanced stage ovarian cancer of epithelial origin - small cell lung carcinoma - carcinoma of the head and neck - carcinoma of the testis - paediatric cerebral tumours - soft tissue sarcoma - neuroblastoma.

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - pegfilgrastim 10 mg/ml - solution for injection - 6 mg/0.6ml - active: pegfilgrastim 10 mg/ml excipient: acetic acid polysorbate 20 sodium hydroxide sorbitol water for injection - ziextenzo is indicated for the reduction in the duration of neutropenia, the incidence of febrile neutropenia and the incidence of infection as manifested by febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - ceftazidime pentahydrate 1164.8mg equivalent to 1 g ceftazidime - powder for injection - 1 g - active: ceftazidime pentahydrate 1164.8mg equivalent to 1 g ceftazidime excipient: nitrogen sodium carbonate - ceftazidime sandoz is indicated for the treatment of single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other beta-lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. indications include: severe infections e.g. septicaemia, bacteraemia, peritonitis, meningitis; infections in immunosuppressed patients; infections in patients in intensive care, e.g. infected burns; respiratory tract infections including lung infections in cystic fibrosis; ear, nose and throat infections; urinary tract infections; skin and soft tissue infections; gastrointestinal, biliary and abdominal infections; bone and joint infections; infections associated with haemo-and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd).

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - ceftazidime pentahydrate 291.2mg equivalent to 250 mg ceftazidime - powder for injection - 250 mg - active: ceftazidime pentahydrate 291.2mg equivalent to 250 mg ceftazidime excipient: nitrogen sodium carbonate - ceftazidime sandoz is indicated for the treatment of single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other beta-lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. indications include: severe infections e.g. septicaemia, bacteraemia, peritonitis, meningitis; infections in immunosuppressed patients; infections in patients in intensive care, e.g. infected burns; respiratory tract infections including lung infections in cystic fibrosis; ear, nose and throat infections; urinary tract infections; skin and soft tissue infections; gastrointestinal, biliary and abdominal infections; bone and joint infections; infections associated with haemo-and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd).

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - ceftazidime pentahydrate 2329.6mg equivalent to 2 g ceftazidime - powder for injection - 2 g - active: ceftazidime pentahydrate 2329.6mg equivalent to 2 g ceftazidime excipient: nitrogen sodium carbonate - ceftazidime sandoz is indicated for the treatment of single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other beta-lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. indications include: severe infections e.g. septicaemia, bacteraemia, peritonitis, meningitis; infections in immunosuppressed patients; infections in patients in intensive care, e.g. infected burns; respiratory tract infections including lung infections in cystic fibrosis; ear, nose and throat infections; urinary tract infections; skin and soft tissue infections; gastrointestinal, biliary and abdominal infections; bone and joint infections; infections associated with haemo-and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd).

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - ceftazidime pentahydrate 582.4mg equivalent to 500 mg ceftazidime - powder for injection - 500 mg - active: ceftazidime pentahydrate 582.4mg equivalent to 500 mg ceftazidime excipient: nitrogen sodium carbonate - ceftazidime sandoz is indicated for the treatment of single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other beta-lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. indications include: severe infections e.g. septicaemia, bacteraemia, peritonitis, meningitis; infections in immunosuppressed patients; infections in patients in intensive care, e.g. infected burns; respiratory tract infections including lung infections in cystic fibrosis; ear, nose and throat infections; urinary tract infections; skin and soft tissue infections; gastrointestinal, biliary and abdominal infections; bone and joint infections; infections associated with haemo-and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd).

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - leuprorelin acetate 3.78mg equivalent to 3.6 mg leuprorelin - subcutaneous implant - 3.6 mg - active: leuprorelin acetate 3.78mg equivalent to 3.6 mg leuprorelin excipient: polyglactin - palliative treatment of patients with advanced, hormone-dependent prostate carcinoma

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - leuprorelin acetate 5.25mg equivalent to leuprorelin 5 mg - subcutaneous implant - 5 mg - active: leuprorelin acetate 5.25mg equivalent to leuprorelin 5 mg excipient: poly(lactide) - palliative treatment of patients with advanced, hormone-dependent prostate carcinoma

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - teriflunomide 14mg;   - film coated tablet - 14 mg - active: teriflunomide 14mg   excipient: colloidal silicon dioxide hyprolose lactose monohydrate magnesium stearate maize starch microcrystalline cellulose opadry blue 03m505004 sodium starch glycolate - teriflunomide sandoz is indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical relapses and to delay the progression of physical disability.